Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus.
Y, Z., Z, L., T, Y., Y, Y., & T, D. (2026). Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus.. BMJ open diabetes research & care. https://doi.org/10.1136/bmjdrc-2025-005841
Y Z, Z L, T Y, Y Y, T D. Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus.. BMJ open diabetes research & care. 2026; doi: 10.1136/bmjdrc-2025-005841
Y Z, Z L, T Y, et al. Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus.[J]. BMJ open diabetes research & care. 2026. DOI: 10.1136/bmjdrc-2025-005841.
@article{y2026,
author = {Zhao Y and Li Z and Yu T and Yang Y and Du T},
title = {Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus.},
journal = {BMJ open diabetes research & care},
year = {2026},
doi = {10.1136/bmjdrc-2025-005841},
note = {PMID: 42303421},
}
TY - JOUR AU - Zhao Y AU - Li Z AU - Yu T AU - Yang Y AU - Du T TI - Discordant high remnant cholesterol with LDL-C increases the metabolic dysfunction-associated steatotic liver disease risk in patients with type 2 diabetes mellitus. T2 - BMJ open diabetes research & care PY - 2026 DO - 10.1136/bmjdrc-2025-005841 AN - PMID:42303421 ER -
INTRODUCTION: Type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist in the same individual. Dyslipidemia plays a central role in the pathogenesis of MASLD. Remnant cholesterol (RC) is the cholesterol content carried in triglyceride-rich lipoproteins. We aimed to examine the association of RC, its discordance with low-density lipoprotein cholesterol (LDL-C) in terms of MASLD risk in patients with T2DM. RESEARCH DESIGN AND METHODS: A total of 26 302 T2DM patients who were hospitalized were cross-sectionally assessed. Logistic regression models were employed to assess the associations. We used three approaches to assess the effects of the discordance between RC and LDL-C on MASLD risk: clinical cut-off points, differences of >10 percentile points and residuals. RESULTS: The median age was 62.0 years, and 48.3% had MASLD. RC was more closely associated with MASLD than LDL-C. Furthermore, discordantly high RC was associated with higher MASLD risk than discordantly high LDL-C, regardless of which method of discordance analysis is used. For example, for the residual approach, in a regression model including LDL-C and RC residual, the latter, representing the portion of RC not explained by LDL-C, was more associated with MASLD risk than LDL-C (OR=1.26, 95% CI 1.22 to 1.30 for RC residual and OR=1.04, 95% CI 1.01 to 1.07 for LDL-C); in a regression model including RC and LDL-C residual, the latter representing the portion of LDL-C not explained by RC, RC was more associated with MASLD risk than LDL-C residual (OR=1.24, 95% CI 1.20 to 1.29 for RC and OR=1.09, 95% CI 1.06 to 1.12 for LDL-C residual). CONCLUSIONS: Discordantly high RC was associated with higher MASLD risk than discordantly high LDL-C. Our findings suggest that RC may serve as a potential target for prevention and intervention for MASLD.